Abcl stock forecast

10 equities research analysts have issued twelve-month

May 4, 2023 at 2:15 PM · 3 min read. AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to ...Price target. 20.75R USD +16.32 +368.40%. The 8 analysts offering 1 year price forecasts for AbCellera Biologics Inc. have a max estimate of 34.00 and a min estimate of 10.00.See the latest AbCellera Biologics Inc Ordinary Shares stock price (ABCL:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Did you know?

Oct 13, 2023 · According to data from CNN Money, the 8 analysts offering 12-month price forecasts for ABCL had a median target of $24.50, with a high estimate of $34.00 and a low estimate of $12.00. This median estimate represents a remarkable increase of +517.13% from the stock’s last price of $3.97. ABCL - Cup & Handle Breakout Trade Abcellera Biologics is a biotech stock setting up in a textbook cup with handle pattern. The stock has growing institutional sponsorship as shown in the chart from MarketSmith on the chart. It also has a relative strength ranking of 97/100. Shares formed a cup with a 37% depth and have since driftAbcellera ... Previous Close $4.4. Volume 1.91M. Average Volume (3M) 1.64M. Market Cap. $1.28B. Enterprise Value $1.28B. Total Cash (Recent Filing) $795.69K. Total Debt (Recent Filing) $84.03K. Price to Earnings (P/E) -9.8. AbCellera Biologics Inc. (ABCL) stock forecast and price target. Find the latest AbCellera Biologics Inc. ABCL analyst stock forecast, price target, and recommendation trends with in-depth ...The current average ABCL price target, as estimated by these analysts, is $27.75. The predictions for the future ABCL stock price range from a low of $18.00 to a high of …All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange ...Wall Street Stock Market & Finance report, prediction for the future: You'll find the Alphabet Inc Class A share forecasts, stock quote and buy / sell signals below. According to present data Alphabet Inc Class A's GOOGL shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists).Get powerful stock screeners & detailed portfolio analysis. Subscribe Now See Plans & Pricing. AbCellera Biologics stock news, updates & related news. Find out why AbCellera Biologics's (ABCL) news sentiment is 14.35% more negative in relation to stocks in the Healthcare sector.Their ACN share price targets range from $279.00 to $410.00. On average, they anticipate the company's stock price to reach $337.26 in the next year. This suggests that the stock has a possible downside of 0.2%. View analysts price targets for ACN or view top-rated stocks among Wall Street analysts.James O'Neil/DigitalVision via Getty Images. AbCellera Biologics ( NASDAQ: ABCL) to date has been quite a lousy investment. From the IPO high of $58.90, all the way down to the current price of ...AbCellera Biologics Inc. company earnings calendar and analyst expectations - Upcoming and past events | Nasdaq: ABCL | NasdaqABCL: AbCellera Biologics - Price and Consensus Chart. Get the latest Price and Consensus Chart for AbCellera Biologics from Zacks Investment ResearchStock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Ownership SEC Filings Short Interest Social Media ABCL vs. SMMT, MRUS, RYZB, ARVN, IRON, AMRX, MRVI, MIRM, PCRX, and PNTADMA Stock 12 Months Forecast. $6.00. (51.90% Upside) Based on 2 Wall Street analysts offering 12 month price targets for ADMA Biologics in the last 3 months. The average price target is $6.00 with a high forecast of $7.00 and a low forecast of $5.00. The average price target represents a 51.90% change from the last price of $3.95.Weather forecasting plays a crucial role in our daFind the latest AbCellera Biologics Inc. ABCL analyst sto ABCL earnings call for the period ending September 30, 2023. Motley Fool Transcribing | Nov 3, 2023 AbCellera Biologics (ABCL) Q2 2023 Earnings Call Transcript AbCellera Biologics saw a drop in short interest in the month o Insiders purchased significant amount of AbCellera stock directly after Q1. See why I ABCL shares are increasingly attractive for long-term, patient investors. ABCL Stock Analysis: Impressive Performance and Optimistic Analyst

Great weather can motivate you to get out of the house, while inclement weather can make you feel lethargic. When the weather’s great we want to be outside enjoying it. For the best regional weather forecasts check out AccuWeather.Lilly(Eli) & Co () Stock Market info Recommendations: Buy or sell Lilly(Eli) stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Lilly(Eli) share forecasts, stock quote and buy / sell signals below.According to present data Lilly(Eli) 's LLY shares and potentially its market environment have been in a bullish cycle in the last …According to 40 analysts, the average rating for MSFT stock is "Strong Buy." The 12-month stock price forecast is $392.0, which is an increase of 3.51% from the latest price.According to our current BILI stock forecast, the value of Bilibili Inc. shares will drop by -8.68% and reach $ 10.31 per share by December 6, 2023. According to our technical indicators, the current sentiment is Bearish while the Fear & Greed Index is showing 39 (Fear).BILI stock recorded 13/30 (43%) green days with 6.20% price …Are you tired of spending countless hours manually tracking your inventory? Are you looking for a way to improve your decision making and forecasting processes? Look no further than a free inventory tracking template.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices. Compare ABCL With Other Stocks. AbCellera Biologics PE Ratio ...hace 4 días ... AbCellera Biologics Inc (NASDAQ:ABCL) shares, rose in value on Thursday, November 30, with the stock price down by -0.31% to the previous ...Analyst Recommendations on AbCellera Biologics Inc. Piper Sandler Assumes AbCellera Biologics at Overweight With $20 Price Target. Oct. 13. MT. Benchmark Adjusts AbCellera Biologics' Price Target to $12 From $20, Keeps Buy Rating. Aug. 31. MT. Goldman Sachs Adjusts AbCellera Biologics' Price Target to $24 From $27, Keeps Buy Rating. …

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. AbCellera Biologics ( ABCL) started trading on the Nas. Possible cause: Key points: Despite only being released into the Australian market a few months ag.

ABCL stock's Price/Earning ratio is 12.33. Our analysis grades ABCL stock's Price / Earning ratio at F. This means that ABCL stock's Price/Earning ratio is above 62% of the stocks in the Biotechnology sector in the NSD exchange. Based on this ABCL may be a overvalued for its sector.Symbol Lookup from Yahoo Finance. Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.

TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comPer our algorithmic AbCellera Biologics stock forecast, ABCL’s price could see a decrease of -13.49% over the next five days and reach $ 4.14 on Dec 05, 2023. In the next month, AbCellera Biologics stock is forecasted to lose -1.11% and hit $ …

AbCellera Biologics Inc. (ABCL) stock forecast an Find the latest AbCellera Biologics Inc. ABCL analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating. Abcellera Biologics Inc (ABCL) Company DescrAfter dumping hundreds of millimetres of rain across New South Wales ABCL stock forecast for 2023 – 2027. Last updated: October 5, 2023. ABCL. AbCellera Biologics Inc. 4.43 D 1.14% (0.05) Are you interested in AbCellera Biologics Inc. stocks prediction? If yes, then on this page you will find useful information about the dynamics of the ABCL stock price in 2022-2027. Is ABCL a good long term stock? When should ...ABCL Stock Forecast - Is ABCL a buy or sell? Find out now with a free analysis on AbCellera Biologics. Should I buy or sell ABCL? ABCL Stock Analysis - [Full Report] ABCL Chart by TradingView. Antibodies Stocks Antibody Stocks Biologics Stocks Database Stocks Drug Stocks Immune Stocks Natural Stocks Even if you do not believe my estimate for $200 million per 19 jul 2023 ... AbCellera Biologics presents a complex yet intriguing investment case. Click here to see why ABCL stock is a Hold. TipRanks | Stock Market Research, News and Real time AbCellera Biologics (ABCL) stock price quote, stock graph,Analyst Forecast. According to 41 analysts, Price Performance Review of ABCL. On Monday, AbCellera Biologics Inc [NASDAQ:ABCL] saw its stock jump 2.91% to $4.60. On the same session, the stock had its day’s lowest price of $4.345, but rose to a high of $4.69. Over the last five days, the stock has gained 15.58%. AbCellera Biologics Inc shares have fallen nearly -54.59% since the year ...15 sept 2023 ... My next multi bagger stock is Abcellera Biologics - stock symbol: ABCL. Victor H Investing•528 views · 12:08 · Go to channel · Community is ... Dec 1, 2023 · ABCL Earnings Date and Information. AbCellera Biol AbCellera Biologics Inc. research and ratings by Barron's. View ABCL revenue estimates and earnings estimates, as well as in-depth analyst breakdowns. Nov 28, 2023 · ABCL stock forecast for 2[Shares of AmerisourceBergen Corp. ABC, sThe average twelve-month price prediction for AbCellera Biologics is Analyst projections state that ABCL is forecast to be at a low of $10.00 and a high of $34.00. In order for the stock price to hit the forecast high, the stock would need to plunge -660.63% from its current level, while the stock would need to crash -123.71% from its current level to reach the projected low.Dec 1, 2023 · https://www.abcellera.com. AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners.